Breaking News Instant updates and real-time market news.

WLTW

Willis Towers Watson

$210.28 /

+1.25 (+0.60%)

08:19
02/10/20
02/10
08:19
02/10/20
08:19

Willis Towers Watson downgraded to Neutral at Credit Suisse

As previously reported, Credit Suisse analyst Michael Zaremski downgraded Willis Towers Watson to Neutral from Outperform on lower conviction that free cash flow levels will spike in 2020-2022. While some of the issues depressing free cash flow such as higher cash taxes and slower account receivable recoupments may only be temporary, the analyst has less confidence that Willis Towers Watson will meaningfully increase its free cash flow conversion rate in the coming years given there are clearly more internal systems/process integration hurdles than he previously appreciated.

  • 10

    Feb

  • 11

    Feb

WLTW Willis Towers Watson
$210.28 /

+1.25 (+0.60%)

02/10/20 Raymond James
Willis Towers Watson price target raised to $240 from $225 at Raymond James
02/10/20 Credit Suisse
Willis Towers Watson downgraded to Neutral from Outperform at Credit Suisse
02/07/20 SunTrust
Willis Towers Watson price target raised to $240 from $225 at SunTrust
01/21/20 Citi
Willis Towers Watson initiated with a Buy at Citi

TODAY'S FREE FLY STORIES

Options
Kohl's call volume above normal and directionally bullish » 12:25
05/26/20
05/26
12:25
05/26/20
12:25
KSS

Kohl's

$19.19 /

+1.7 (+9.72%)

Bullish option flow…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
KSS Kohl's
$19.19 /

+1.7 (+9.72%)

KSS Kohl's
$19.19 /

+1.7 (+9.72%)

05/20/20 Deutsche Bank
Kohl's price target lowered to $23 from $26 at Deutsche Bank
05/07/20 Deutsche Bank
Kohl's price target lowered to $26 from $45 at Deutsche Bank
04/27/20 Guggenheim
Kohl's price target lowered to $25 from $50 at Guggenheim
03/27/20 Cleveland Research
Kohl's downgraded at Cleveland Research, says March-to-date comps down 50%
KSS Kohl's
$19.19 /

+1.7 (+9.72%)

KSS Kohl's
$19.19 /

+1.7 (+9.72%)

KSS Kohl's
$19.19 /

+1.7 (+9.72%)

KSS Kohl's
$19.19 /

+1.7 (+9.72%)

Conference/Events
Alexion participates in a conference call with Credit Suisse » 12:25
05/26/20
05/26
12:25
05/26/20
12:25
ALXN

Alexion

$104.26 /

+2.72 (+2.68%)

Management discusses…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ALXN Alexion
$104.26 /

+2.72 (+2.68%)

ALXN Alexion
$104.26 /

+2.72 (+2.68%)

11:47 Today Piper Sandler
Piper stays Overweight Alexion after Argenx data, says comps 'near impossible'
07:25 Today Credit Suisse
Skepticism may create overlooked value in Alexion pipeline, says Credit Suisse
05/15/20 H.C. Wainwright
H.C. Wainwright calls Sarepta 'best of breed' after Pfizer DMD data
05/06/20 Piper Sandler
Piper Sandler remains buyer of Alexion despite frustration
ALXN Alexion
$104.26 /

+2.72 (+2.68%)

ALXN Alexion
$104.26 /

+2.72 (+2.68%)

ALXN Alexion
$104.26 /

+2.72 (+2.68%)

ALXN Alexion
$104.26 /

+2.72 (+2.68%)

Conference/Events
Wolfe Research transport analyst to hold analyst/industry webcast » 12:25
05/26/20
05/26
12:25
05/26/20
12:25

Transports Analyst Group…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Conference/Events
Krystal Biotech participates in a conference call with Cowen » 12:25
05/26/20
05/26
12:25
05/26/20
12:25
KRYS

Krystal Biotech

$53.39 /

+0.385 (+0.73%)

Biotech Analyst Baral…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
KRYS Krystal Biotech
$53.39 /

+0.385 (+0.73%)

KRYS Krystal Biotech
$53.39 /

+0.385 (+0.73%)

03/12/20 SMBC Nikko
Krystal Biotech initiated with an Outperform at SMBC Nikko
03/10/20 H.C. Wainwright
Krystal Biotech price target raised to $68 from $59 at H.C. Wainwright
09/26/19 Guggenheim
Krystal Biotech has 'room to run' despite doubling year-to-date, says Guggenheim
09/24/19 Goldman Sachs
Krystal Biotech initiated with a Neutral at Goldman Sachs
KRYS Krystal Biotech
$53.39 /

+0.385 (+0.73%)

KRYS Krystal Biotech
$53.39 /

+0.385 (+0.73%)

Conference/Events
Equinix participates in a conference call with SunTrust » 12:22
05/26/20
05/26
12:22
05/26/20
12:22
EQIX

Equinix

$664.29 /

-6.31 (-0.94%)

Conference call with…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
EQIX Equinix
$664.29 /

-6.31 (-0.94%)

EQIX Equinix
$664.29 /

-6.31 (-0.94%)

05/13/20 RBC Capital
Equinix price target raised to $706 from $688 at RBC Capital
05/07/20 Wells Fargo
Equinix price target raised to $745 from $675 at Wells Fargo
05/07/20 JPMorgan
Equinix price target raised to $725 from $675 at JPMorgan
04/27/20 JPMorgan
JPMorgan positive on data center demand, Equinix top large cap pick
EQIX Equinix
$664.29 /

-6.31 (-0.94%)

EQIX Equinix
$664.29 /

-6.31 (-0.94%)

EQIX Equinix
$664.29 /

-6.31 (-0.94%)

Conference/Events
Equinix participates in a conference call with SunTrust » 12:22
05/26/20
05/26
12:22
05/26/20
12:22
EQIX

Equinix

$664.29 /

-6.31 (-0.94%)

Conference call with…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EQIX Equinix
$664.29 /

-6.31 (-0.94%)

EQIX Equinix
$664.29 /

-6.31 (-0.94%)

05/13/20 RBC Capital
Equinix price target raised to $706 from $688 at RBC Capital
05/07/20 Wells Fargo
Equinix price target raised to $745 from $675 at Wells Fargo
05/07/20 JPMorgan
Equinix price target raised to $725 from $675 at JPMorgan
04/27/20 JPMorgan
JPMorgan positive on data center demand, Equinix top large cap pick
EQIX Equinix
$664.29 /

-6.31 (-0.94%)

EQIX Equinix
$664.29 /

-6.31 (-0.94%)

EQIX Equinix
$664.29 /

-6.31 (-0.94%)

Technical Analysis
NASDAQ market internals summary » 12:17
05/26/20
05/26
12:17
05/26/20
12:17
$NSD

NASDAQ Market Internals

$0.00 /

+ (+0.00%)

Volume is above average…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
$NSD NASDAQ Market Internals
$0.00 /

+ (+0.00%)

Technical Analysis
NYSE market internals summary » 12:16
05/26/20
05/26
12:16
05/26/20
12:16
$NYE

NYSE Market Internals

$0.00 /

+ (+0.00%)

Volume is above average…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
$NYE NYSE Market Internals
$0.00 /

+ (+0.00%)

Options
Ringcentral put volume heavy and directionally bearish » 12:15
05/26/20
05/26
12:15
05/26/20
12:15
RNG

RingCentral

$252.00 /

-9.75 (-3.72%)

Bearish flow noted in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
RNG RingCentral
$252.00 /

-9.75 (-3.72%)

RNG RingCentral
$252.00 /

-9.75 (-3.72%)

05/11/20 Jefferies
Avaya Q2 comments a positive read-through for RingCentral, says Jefferies
05/07/20 Wells Fargo
RingCentral price target raised to $285 from $280 at Wells Fargo
05/07/20 Oppenheimer
RingCentral price target raised to $270 from $240 at Oppenheimer
05/07/20 Raymond James
RingCentral price target raised to $290 from $250 at Raymond James
RNG RingCentral
$252.00 /

-9.75 (-3.72%)

RNG RingCentral
$252.00 /

-9.75 (-3.72%)

RNG RingCentral
$252.00 /

-9.75 (-3.72%)

RNG RingCentral
$252.00 /

-9.75 (-3.72%)

Syndicate
Infineon announces EUR 1B capital raise through new shares » 12:10
05/26/20
05/26
12:10
05/26/20
12:10
IFNNY

Infineon

$0.00 /

+ (+0.00%)

Infineon Technologies…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
IFNNY Infineon
$0.00 /

+ (+0.00%)

IFNNY Infineon
$0.00 /

+ (+0.00%)

06:21 Today JMP Securities
Cree upgraded to Outperform from Market Perform at JMP Securities
05/12/20 Goldman Sachs
Infineon downgraded to Neutral from Buy at Goldman Sachs
05/06/20 Deutsche Bank
Infineon price target lowered to EUR 22 from EUR 23 at Deutsche Bank
05/06/20 UBS
Infineon price target raised to EUR 23.50 from EUR 22 at UBS
IFNNY Infineon
$0.00 /

+ (+0.00%)

IFNNY Infineon
$0.00 /

+ (+0.00%)

IFNNY Infineon
$0.00 /

+ (+0.00%)

Initiation
Silvercorp Metals resumed with a Market Perform at BMO Capital » 12:08
05/26/20
05/26
12:08
05/26/20
12:08
SVM

Silvercorp Metals

$4.10 /

-0.015 (-0.36%)

BMO Capital analyst Ryan…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SVM Silvercorp Metals
$4.10 /

-0.015 (-0.36%)

SVM Silvercorp Metals
$4.10 /

-0.015 (-0.36%)

04/28/20 BMO Capital
Silvercorp Metals price target raised to C$5.50 from C$5.25 at BMO Capital
03/11/20 Alliance Global Partners
Silvercorp Metals upgraded to Buy from Neutral at Alliance Global Partners
11/12/19 Alliance Global Partners
Silvercorp Metals downgraded to Neutral from Buy at Alliance Global Partners
09/11/19 BMO Capital
Silvercorp Metals downgraded to Market Perform from Outperform at BMO Capital
SVM Silvercorp Metals
$4.10 /

-0.015 (-0.36%)

SVM Silvercorp Metals
$4.10 /

-0.015 (-0.36%)

Options
Frontline call volume above normal and directionally bullish » 12:05
05/26/20
05/26
12:05
05/26/20
12:05
FRO

Frontline

$8.46 /

+0.38 (+4.71%)

Bullish option flow…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FRO Frontline
$8.46 /

+0.38 (+4.71%)

FRO Frontline
$8.46 /

+0.38 (+4.71%)

05/04/20 Evercore ISI
Frontline downgraded to In Line from Outperform at Evercore ISI
03/24/20 Jefferies
Jefferies upgrades Frontline to Buy on strong tanker market
03/24/20 Jefferies
Frontline upgraded to Buy from Hold at Jefferies
03/09/20 DNB Markets
Frontline downgraded to Hold from Buy at DNB Markets
FRO Frontline
$8.46 /

+0.38 (+4.71%)

FRO Frontline
$8.46 /

+0.38 (+4.71%)

On The Fly
Argenx jumps after efgartigimod hits goals in late-stage study » 12:02
05/26/20
05/26
12:02
05/26/20
12:02
ALXN

Alexion

$104.24 /

+2.7 (+2.66%)

, ARGX

Argenx

$210.24 /

+51.98 (+32.84%)

, MNTA

Momenta

$32.82 /

+0.07 (+0.21%)

Shares of Argenx (ARGX)…

Open Full Text

ShowHide Related Items >><<
ALXN Alexion
$104.24 /

+2.7 (+2.66%)

ARGX Argenx
$210.24 /

+51.98 (+32.84%)

MNTA Momenta
$32.82 /

+0.07 (+0.21%)

ALXN Alexion
$104.24 /

+2.7 (+2.66%)

11:47 Today Piper Sandler
Piper stays Overweight Alexion after Argenx data, says comps 'near impossible'
07:25 Today Credit Suisse
Skepticism may create overlooked value in Alexion pipeline, says Credit Suisse
05/15/20 H.C. Wainwright
H.C. Wainwright calls Sarepta 'best of breed' after Pfizer DMD data
05/06/20 Piper Sandler
Piper Sandler remains buyer of Alexion despite frustration
ARGX Argenx
$210.24 /

+51.98 (+32.84%)

11:47 Today Piper Sandler
Piper stays Overweight Alexion after Argenx data, says comps 'near impossible'
08:01 Today Stifel
Argenx's results in MG should read through positively for Momenta, says Stifel
07:35 Today Piper Sandler
Argenx price target raised to $258 from $198 at Piper Sandler
07:08 Today Stifel
Argenx should trade up to 'mid-$180 range' after trial success, says Stifel
MNTA Momenta
$32.82 /

+0.07 (+0.21%)

08:01 Today Stifel
Argenx's results in MG should read through positively for Momenta, says Stifel
05/08/20 H.C. Wainwright
Momenta price target raised to $40 from $36 at H.C. Wainwright
04/02/20 H.C. Wainwright
Momenta's Vivacity-MG still on track despite COVID-19, says H.C. Wainwright
04/02/20 Piper Sandler
Piper Sandler says enrollment delays already priced into Momenta shares
ALXN Alexion
$104.24 /

+2.7 (+2.66%)

MNTA Momenta
$32.82 /

+0.07 (+0.21%)

ALXN Alexion
$104.24 /

+2.7 (+2.66%)

ALXN Alexion
$104.24 /

+2.7 (+2.66%)

ARGX Argenx
$210.24 /

+51.98 (+32.84%)

MNTA Momenta
$32.82 /

+0.07 (+0.21%)

ALXN Alexion
$104.24 /

+2.7 (+2.66%)

Upgrade
Astellas Pharma upgraded to Buy on raised PADCEV estimates at Goldman Sachs » 12:01
05/26/20
05/26
12:01
05/26/20
12:01
ALPMY

Astellas Pharma

$0.00 /

+ (+0.00%)

, SGEN

Seattle Genetics

$156.65 /

+0.88 (+0.56%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ALPMY Astellas Pharma
$0.00 /

+ (+0.00%)

SGEN Seattle Genetics
$156.65 /

+0.88 (+0.56%)

ALPMY Astellas Pharma
$0.00 /

+ (+0.00%)

11:56 Today Goldman Sachs
Astellas Pharma upgraded to Buy from Neutral at Goldman Sachs
01/23/20 Morgan Stanley
Astellas Pharma resumed with an Overweight at Morgan Stanley
12/05/19 JPMorgan
Audentes Therapeutics downgraded to Neutral from Overweight at JPMorgan
12/03/19 Raymond James
Audentes downgraded to Market Perform from Outperform at Raymond James
SGEN Seattle Genetics
$156.65 /

+0.88 (+0.56%)

07:24 Today JMP Securities
Seattle Genetics initiated with an Outperform at JMP Securities
05:40 Today Goldman Sachs
Incyte downgraded to Buy from Conviction Buy at Goldman Sachs
05:38 Today Goldman Sachs
Seattle Genetics upgraded to Conviction Buy from Buy at Goldman Sachs
05/01/20
Fly Intel: Top five analyst upgrades
SGEN Seattle Genetics
$156.65 /

+0.88 (+0.56%)

ALPMY Astellas Pharma
$0.00 /

+ (+0.00%)

ALPMY Astellas Pharma
$0.00 /

+ (+0.00%)

SGEN Seattle Genetics
$156.65 /

+0.88 (+0.56%)

Hot Stocks
Debt Resolve falls -9.5% » 12:00
05/26/20
05/26
12:00
05/26/20
12:00
DRV

Debt Resolve

$19.88 /

-2.08 (-9.47%)

Debt Resolve is down…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
DRV Debt Resolve
$19.88 /

-2.08 (-9.47%)

Hot Stocks
FGL Holdings falls -10.3% » 12:00
05/26/20
05/26
12:00
05/26/20
12:00
FG

FGL Holdings

$9.48 /

-1.1 (-10.40%)

FGL Holdings is down…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FG FGL Holdings
$9.48 /

-1.1 (-10.40%)

FG FGL Holdings
$9.48 /

-1.1 (-10.40%)

03/20/20 RBC Capital
RBC Capital sees some time before Life Insurance returns to 'normal'
03/20/20 RBC Capital
FGL Holdings downgraded to Sector Perform from Outperform at RBC Capital
02/10/20 Piper Sandler
FGL Holdings downgraded to Neutral from Overweight at Piper Sandler
02/10/20 Goldman Sachs
FGL Holdings upgraded to Neutral from Sell at Goldman Sachs
FG FGL Holdings
$9.48 /

-1.1 (-10.40%)

FG FGL Holdings
$9.48 /

-1.1 (-10.40%)

FG FGL Holdings
$9.48 /

-1.1 (-10.40%)

Hot Stocks
Direxion Financial Bear 3x falls -10.8% » 12:00
05/26/20
05/26
12:00
05/26/20
12:00
FAZ

Direxion Financial Bear 3x

$20.72 /

-2.52 (-10.84%)

Direxion Financial Bear…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
FAZ Direxion Financial Bear 3x
$20.72 /

-2.52 (-10.84%)

FAZ Direxion Financial Bear 3x
$20.72 /

-2.52 (-10.84%)

Hot Stocks
Spirit Airlines rises 18.1% » 12:00
05/26/20
05/26
12:00
05/26/20
12:00
SAVE

Spirit Airlines

$12.03 /

+1.86 (+18.29%)

Spirit Airlines is up…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SAVE Spirit Airlines
$12.03 /

+1.86 (+18.29%)

SAVE Spirit Airlines
$12.03 /

+1.86 (+18.29%)

05/18/20 Evercore ISI
Spirit Airlines upgraded to Outperform from In Line at Evercore ISI
05/13/20
Fly Intel: Top five analyst downgrades
05/13/20 Raymond James
Spirit Airlines downgraded to Market Perform from Outperform at Raymond James
05/13/20 Citi
Citi opens positive '90-day catalyst watch' on Spirit despite target cut
SAVE Spirit Airlines
$12.03 /

+1.86 (+18.29%)

SAVE Spirit Airlines
$12.03 /

+1.86 (+18.29%)

SAVE Spirit Airlines
$12.03 /

+1.86 (+18.29%)

SAVE Spirit Airlines
$12.03 /

+1.86 (+18.29%)

Hot Stocks
Viad rises 19.4% » 12:00
05/26/20
05/26
12:00
05/26/20
12:00
VVI

Viad

$19.23 /

+3.22 (+20.11%)

Viad is up 19.4%, or…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VVI Viad
$19.23 /

+3.22 (+20.11%)

VVI Viad
$19.23 /

+3.22 (+20.11%)

VVI Viad
$19.23 /

+3.22 (+20.11%)

Hot Stocks
Fly Leasing rises 29.3% » 12:00
05/26/20
05/26
12:00
05/26/20
12:00
FLY

Fly Leasing

$8.02 /

+1.875 (+30.54%)

Fly Leasing is up 29.3%,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FLY Fly Leasing
$8.02 /

+1.875 (+30.54%)

FLY Fly Leasing
$8.02 /

+1.875 (+30.54%)

09:22 Today JPMorgan
JPMorgan upgrades Fly Leasing with stock rally lagging peers
05:31 Today JPMorgan
Fly Leasing upgraded to Overweight from Neutral at JPMorgan
05/11/20 Deutsche Bank
Fly Leasing price target lowered to $10 from $20 at Deutsche Bank
10/21/19 JPMorgan
Fly Leasing upgraded to Neutral following underperformance at JPMorgan
FLY Fly Leasing
$8.02 /

+1.875 (+30.54%)

Hot Stocks
Allakos drops after Regeneron eosinophilic esophagitis study hits endpoints » 11:57
05/26/20
05/26
11:57
05/26/20
11:57
ALLK

Allakos

$68.56 /

-8.22 (-10.71%)

, REGN

Regeneron

$540.70 /

-29.24 (-5.13%)

Shares of Allakos (ALLK)…

Shares of Allakos (ALLK) are lower after Regeneron Pharmaceuticals (REGN) announced yesterday that Part A of a Phase 3 trial evaluating Dupixent in patients 12 years and older with eosinophilic esophagitis met both of its co-primary endpoints as well as all key secondary endpoints. Dupixent is the "first and only biologic to show positive and clinically-meaningful results in this population as part of a Phase 3 trial," Regeneron said in a statement. The drug showed a 69% reduction in disease symptoms compared to 32% for placebo and a 60% reduction in esophageal eosinophilic count to a normal range compared to 5% for placebo. Allakos is developing antolimab for the treatment of eosinophil and mast cell related diseases and has a Phase 2/3 study in eosinophilic esophagitis. "These data don't leave much room for Allakos to win with antolimab," STAT's Adam Feuerstein tweeted. Shares of Allakos are down 10%, or $7.41, to $69.15 in midday trading.

ShowHide Related Items >><<
ALLK Allakos
$68.56 /

-8.22 (-10.71%)

REGN Regeneron
$540.70 /

-29.24 (-5.13%)

ALLK Allakos
$68.56 /

-8.22 (-10.71%)

03/25/20 Jefferies
Allakos starts two pivotals on time despite skepticism, says Jefferies
03/12/20 SMBC Nikko
Allakos initiated with an Underperform at SMBC Nikko
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
02/27/20 Barclays
Allakos initiated with an Underweight at Barclays
REGN Regeneron
$540.70 /

-29.24 (-5.13%)

10:08 Today
Fly Intel: Top five analyst upgrades
09:33 Today RBC Capital
BioMarin among Sanofi's most intriguing potential targets, says RBC Capital
09:09 Today Piper Sandler
Piper remains buyer of Regeneron, ups target to $630 on buyback accretion
08:24 Today SVB Leerink
Sanofi overhang removed, Regeneron capital structure improving, says SVB Leerink
ALLK Allakos
$68.56 /

-8.22 (-10.71%)

REGN Regeneron
$540.70 /

-29.24 (-5.13%)

  • 27
    May
ALLK Allakos
$68.56 /

-8.22 (-10.71%)

REGN Regeneron
$540.70 /

-29.24 (-5.13%)

ALLK Allakos
$68.56 /

-8.22 (-10.71%)

REGN Regeneron
$540.70 /

-29.24 (-5.13%)

REGN Regeneron
$540.70 /

-29.24 (-5.13%)

Upgrade
Astellas Pharma upgraded to Buy from Neutral at Goldman Sachs » 11:56
05/26/20
05/26
11:56
05/26/20
11:56
ALPMY

Astellas Pharma

$0.00 /

+ (+0.00%)

Goldman Sachs upgraded…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ALPMY Astellas Pharma
$0.00 /

+ (+0.00%)

ALPMY Astellas Pharma
$0.00 /

+ (+0.00%)

01/23/20 Morgan Stanley
Astellas Pharma resumed with an Overweight at Morgan Stanley
12/05/19 JPMorgan
Audentes Therapeutics downgraded to Neutral from Overweight at JPMorgan
12/03/19 Raymond James
Audentes downgraded to Market Perform from Outperform at Raymond James
12/03/19 H.C. Wainwright
Audentes Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
ALPMY Astellas Pharma
$0.00 /

+ (+0.00%)

ALPMY Astellas Pharma
$0.00 /

+ (+0.00%)

Downgrade
Kainos Group downgraded to Hold from Buy at Canaccord » 11:55
05/26/20
05/26
11:55
05/26/20
11:55
KNNNF

Kainos Group

$0.00 /

+ (+0.00%)

Canaccord analyst Kai…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Options
Logitech put volume heavy and directionally bearish » 11:55
05/26/20
05/26
11:55
05/26/20
11:55
LOGI

Logitech

$57.30 /

+0.85 (+1.51%)

Bearish flow noted in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LOGI Logitech
$57.30 /

+0.85 (+1.51%)

LOGI Logitech
$57.30 /

+0.85 (+1.51%)

05/21/20
Fly Intel: Top five analyst downgrades
05/21/20 JPMorgan
Logitech downgraded to Neutral on valuation at JPMorgan
05/21/20 JPMorgan
Logitech downgraded to Neutral from Overweight at JPMorgan
05/20/20
Fly Intel: Top five analyst upgrades
LOGI Logitech
$57.30 /

+0.85 (+1.51%)

LOGI Logitech
$57.30 /

+0.85 (+1.51%)

LOGI Logitech
$57.30 /

+0.85 (+1.51%)

General news
Treasury's $117 B 3- and 6-month bill auctions priced well » 11:55
05/26/20
05/26
11:55
05/26/20
11:55

Treasury's $117 B 3-…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.